DOCSLIB.ORG

Connective Tissue Diseases, Multimorbidity and the Ageing Lung

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Connective Tissue Diseases, Multimorbidity and the Ageing Lung STATE OF THE ART | MULTIMORBIDITY AND THE LUNG Connective tissue diseases, multimorbidity and the ageing lung Paolo Spagnolo1, Jean-François Cordier2,3 and Vincent Cottin2,3,4 Number 8 in the series “Multimorbidity and the lung” Edited by L.M. Fabbri and J.M. Drazen Affiliations: 1Medical University Clinic, Canton Hospital Baselland, and University of Basel, Liestal, Switzerland. 2Hospices Civils de Lyon, Hôpital Louis Pradel, National Reference Center for Rare Pulmonary Diseases, Lyon, France. 3Claude Bernard Lyon 1 University, University of Lyon, Lyon, France. 4INRA, UMR754, Lyon, France. Correspondence: Vincent Cottin, Hôpital Louis Pradel, F-69677 Lyon Cedex, France. E-mail: [email protected] ABSTRACT Connective tissue diseases encompass a wide range of heterogeneous disorders characterised by immune-mediated chronic inflammation often leading to tissue damage, collagen deposition and possible loss of function of the target organ. Lung involvement is a common complication of connective tissue diseases. Depending on the underlying disease, various thoracic compartments can be involved but interstitial lung disease is a major contributor to morbidity and mortality. Interstitial lung disease, pulmonary hypertension or both are found most commonly in systemic sclerosis. In the elderly, the prevalence of connective tissue diseases continues to rise due to both longer life expectancy and more effective and better-tolerated treatments. In the geriatric population, connective tissue diseases are almost invariably accompanied by age-related comorbidities, and disease- and treatment-related complications, which contribute to the significant morbidity and mortality associated with these conditions, and complicate treatment decision-making. Connective tissue diseases in the elderly represent a growing concern for healthcare providers and an increasing burden of global health resources worldwide. A better understanding of the mechanisms involved in the regulation of the immune functions in the elderly and evidence-based guidelines specifically designed for this patient population are instrumental to improving the management of connective tissue diseases in elderly patients. @ERSpublications CTDs in the elderly are often complicated by comorbidities with important prognostic implications http://ow.ly/XUbv1 Previous articles in this series: No. 1: Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775–788. No. 2: Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44: 1055–1068. No. 3: MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J 2014; 44: 1332–1352. No. 4: Carraro S, Scheltema N, Bont L, et al. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur Respir J 2014; 44: 1682–1696. No. 5: Chacko A, Carpenter DO, Callaway L, et al. Early-life risk factors for chronic nonrespiratory diseases. Eur Respir J 2015; 45: 244–259. No. 6: Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J 2015; 45: 790–806. No. 7: Rodriguez-Roisin R, Bartolome SD, Huchon G, et al. Inflammatory bowel diseases, chronic liver diseases and the lung. Eur Respir J 2016; 47: 638–650. Received: May 26 2015 | Accepted after revision: Jan 23 2016 | First published online: Feb 25 2016 Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com Copyright ©ERS 2016 Eur Respir J 2016; 47: 1535–1558 | DOI: 10.1183/13993003.00829-2015 1535 MULTIMORBIDITY AND THE LUNG | P. SPAGNOLO ET AL. Age does not depend upon years, but upon temperament and health. Some men are born old, and some never grow so. Tryon Edwards Introduction The term connective tissue disease (CTD) refers to a large and heterogeneous group of immunologically mediated disorders characterised by inflammation, tissue damage and abnormal repair, often leading to degeneration of the target organ, replacement by fibrotic tissue and loss of function. These disorders are multifactorial in origin, with a complex interaction between genetic and environmental factors contributing to their development [1]. CTDs are often complicated by comorbidity [2], which is defined as “the existence or occurrence of any distinct additional entity during the clinical course of a patient who has the index disease under study” [3]. Accordingly, comorbidity includes: 1) conditions directly pathophysiologically linked to the index disease (e.g. cardiovascular disease following rheumatoid arthritis); 2) complications resulting from treatment of the index disease (e.g. glucocorticoid-induced diabetes mellitus); and 3) conditions indirectly linked to the disease or its management (e.g. infection in rheumatoid arthritis) [4]. Comorbidities are associated with increased use of multiple therapies and, therefore, higher risk of drug interactions. However, multimorbidity, defined as the coexistence of two or more chronic diseases in the same individual, irrespective of whether the disease started before or after the onset of the index disease, is far more common in CTDs, particularly in an ageing patient population [5]. In multimorbidity, no index disease is defined and all morbidities are regarded of equal importance. Both comorbidities and multimorbidities impact significantly on patients’ health as they reduce quality of life and life expectancy, and add considerable complexity to patient care [4]. Not surprisingly, greater healthcare utilisation accompanies this higher chronicity burden [6]. Because treatment options for CTDs have become increasingly effective (and better tolerated), patient survival has improved. As a consequence, the impact of comorbid conditions in individuals suffering from these disorders has become a growing concern for healthcare providers. The lung is a frequent target of autoimmune-mediated injury in patients with CTDs by virtue of its abundant connective tissue and blood supply, and pulmonary involvement is a leading cause of morbidity and mortality in this setting. All compartments can be affected (e.g. airways, lung parenchyma, vasculature and pleura), though in various degrees and combinations depending on the underlying disease [7] (tables 1 and 2). CTDs in the elderly: prevalence and disease burden Rheumatoid arthritis Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by erosive inflammatory polyarthropathy with symmetric polyarthritis. RA affects approximately 1% of the population worldwide, and women are twice as likely as men to be affected (table 3) [8]. While RA can occur in individuals of any age, with the peak incidence being observed between the fourth and sixth decade, its incidence TABLE 1 Types of lung involvement in connective tissue diseases Primary manifestations Pleural involvement Pleurisy, effusion/thickening Airway disease Cricoarytenoid and tracheal involvement Bronchiectasis, bronchiolitis Vascular involvement Pulmonary hypertension Vasculitis Parenchymal lung disease Interstitial lung disease Diffuse alveolar haemorrhage Acute pneumonitis Rheumatoid nodules Secondary manifestations Infection Drug toxicity Malignancy Thromboembolism 1536 DOI: 10.1183/13993003.00829-2015 MULTIMORBIDITY AND THE LUNG | P. SPAGNOLO ET AL. TABLE 2 Common pulmonary manifestations in connective tissue diseases Manifestation RA SSc SS SLE PM/DM MCTD AS Pleural disease# ++ − + +++ − + − Airway disease¶ ++ − ++ + − + − Interstitial lung disease ++ +++ ++ + +++ ++ + DAD + + + ++ + + − DAH and capillaritis + − ++ −−− OP ++ + + + +++ + − NSIP + +++ ++ ++ +++ ++ + UIP +++ + + + + + − LIP + − +++ + −−− Vascular disease + +++ + + + ++ − Pulmonary hypertension + +++ + + − + − Parenchymal nodules + −−− − − − Apical fibrobullous disease + −−− − −+++ Respiratory muscle dysfunction −−−+++ ++ + − Aspiration pneumonia − +++ −− ++− The signs indicate the frequency of each manifestation (i.e. −: rare/not described; +: low prevalence; ++: medium prevalence; +++: high prevalence). RA: rheumatoid arthritis; SSc: systemic sclerosis; SS: Sjögren’s syndrome; SLE: systemic lupus erythematosus; PM: polymyositis; DM: dermatomyositis; MCTD: mixed connective tissue disease; AS: ankylosing spondylitis; DAD: diffuse alveolar damage; DAH: diffuse alveolar haemorrhage; OP: organising pneumonia; NSIP: nonspecific interstitial pneumonia; UIP: usual interstitial pneumonia; LIP: lymphocytic interstitial pneumonia. #: inflammation, fibrosis or effusion; ¶: inflammation, obstruction or lymphoid hyperplasia. continues to increase with age, while its prevalence becomes almost equal in both sexes [9]. The term “elderly-onset RA” refers to the de novo development of the disease at age 60 years or older, yet in most patients in this age group, RA represents the persistence of a disease that manifested clinically at a younger age (young-onset RA). Compared with young-onset RA, elderly-onset RA is characterised by a higher frequency of acute onset and more frequent involvement of large joints [10] (table 4). Systemic sclerosis Systemic sclerosis (SSc) is an uncommon disease characterised by endothelial and epithelial cell injury, fibroblast dysregulation, and immune system abnormalities leading to systemic inflammation, fibrosis of target organs and vascular damage [11]. Clinical forms range from mild, limited skin involvement (limited cutaneous SSc) to widespread skin thickening and severe internal organ involvement (diffuse
Load more

Recommended publications
  • Acute < 6 Weeks Subacute ~ 6 Weeks Chronic >
    Pain Articular Non-articular Localized Generalized . Regional Pain Disorders . Myalgias without Weakness Soft Tissue Rheumatism (ex., fibromyalgia, polymyalgia (ex., soft tissue rheumatism rheumatica) tendonitis, tenosynovitis, bursitis, fasciitis) . Myalgia with Weakness (ex., Inflammatory muscle disease) Clinical Features of Arthritis Monoarthritis Oligoarthritis Polyarthritis (one joint) (two to five joints) (> five joints) Acute < 6 weeks Subacute ~ 6 weeks Chronic > 6 weeks Inflammatory Noninflammatory Differential Diagnosis of Arthritis Differential Diagnosis of Arthritis Acute Monarthritis Acute Polyarthritis Inflammatory Inflammatory . Infection . Viral - gonococcal (GC) - hepatitis - nonGC - parvovirus . Crystal deposition - HIV - gout . Rheumatic fever - calcium . GC - pyrophosphate dihydrate (CPPD) . CTD (connective tissue diseases) - hydroxylapatite (HA) - RA . Spondyloarthropathies - systemic lupus erythematosus (SLE) - reactive . Sarcoidosis - psoriatic . - inflammatory bowel disease (IBD) Spondyloarthropathies - reactive - Reiters . - psoriatic Early RA - IBD - Reiters Non-inflammatory . Subacute bacterial endocarditis (SBE) . Trauma . Hemophilia Non-inflammatory . Avascular Necrosis . Hypertrophic osteoarthropathy . Internal derangement Chronic Monarthritis Chronic Polyarthritis Inflammatory Inflammatory . Chronic Infection . Bony erosions - fungal, - RA/Juvenile rheumatoid arthritis (JRA ) - tuberculosis (TB) - Crystal deposition . Rheumatoid arthritis (RA) - Infection (15%) - Erosive OA (rare) Non-inflammatory - Spondyloarthropathies
    [Show full text]
  • Axial Spondyloarthritis
    Central JSM Arthritis Review Article *Corresponding author Mali Jurkowski, Department of Internal Medicine, Temple University Hospital, 3401 North Broad Street, Axial Spondyloarthritis: Clinical Philadelphia, PA 19140, USA Submitted: 07 December 2020 Features, Classification, and Accepted: 31 January 2021 Published: 03 February 2021 ISSN: 2475-9155 Treatment Copyright Mali Jurkowski1*, Stephanie Jeong1 and Lawrence H Brent2 © 2021 Jurkowski M, et al. 1Department of Internal Medicine, Temple University Hospital, USA OPEN ACCESS 2Section of Rheumatology, Department of Medicine, Lewis Katz School of Medicine at Temple University, USA Keywords ABBREVIATIONS • Spondyloarthritis • Ankylosing spondylitis HLA-B27: human leukocyte antigen-B27; SpA: • HLA-B27 spondyloarthritis; AS: ankylosing spondylitis; nr-axSpA: non- • Classification criteria radiographic axial spondyloarthritis; ReA: reactive arthritis; PsA: psoriatic arthritis; IBD-SpA: disease associated spondyloarthritis; ASAS: Assessment of of rheumatoid arthritis [6]. AS affects men more than women SpondyloArthritis international Society; NSAIDs:inflammatory nonsteroidal bowel 79.6%, whereas nr-axSpA affects men and women equally 72.4% CASPAR: [7], independent of HLA-B27. This article will discuss the clinical for Psoriatic Arthritis; DMARDs: disease modifying anti- and diagnostic features of SpA, compare the classification criteria, rheumaticanti-inflammatory drugs; CD:drugs; Crohn’s disease; ClassificationUC: ulcerative Criteriacolitis; and provide updates regarding treatment options, including the ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; developmentCLINICAL FEATURESof biologics and targeted synthetic agents. TNFi: X-ray: plain radiography; MRI: magnetic resonance imaging; CT: computed Inflammatory back pain tomography;tumor US: necrosis ultrasonography; factor-α wb-MRI:inhibitors; ESSG: European Spondyloarthropathy Study Group; IL-17i: whole-body MRI; JAKi: PDE4i: Inflammatory back pain is the hallmark of SpA, present in 70- 80% of patients [8].
    [Show full text]
  • Charcot Arthropathy: Differential Diagnosis of Inflammatory Arthritis
    CHARCOT ARTHROPATHY: DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY ARTHRITIS CAMILA DA SILVA CENDON DURAN (USP-SP, SÃO PAULO, SP, Brasil), CARLA BALEEIRO RODRIGUES SILVA (USP-SP, SÃO PAULO, SP, Brasil), CARLO SCOGNAMIGLIO RENNER ARAUJO (USP-SP, SÃO PAULO, SP, Brasil), LUCAS BRANDÃO ARAUJO DA SILVA (USP-SP, SÃO PAULO, SP, Brasil), LUCIANA PARENTE COSTA SEGURO (USP-SP, SÃO PAULO, SP, Brasil), LISSIANE KARINE NORONHA GUEDES (USP-SP, SÃO PAULO, SP, Brasil), ROSA MARIA RODRIGUES PEREIRA (USP-SP, SÃO PAULO, SP, Brasil), EDUARDO FERREIRA BORBA NETO (USP-SP, SÃO PAULO, SP, Brasil) BACKGROUND Charcot-Marie-Tooth Disease (CMT) is the most common hereditary neuropathy, with an estimated prevalence of 40 cases per 100,000 individuals. CMT type 2, the most common subtype, is an axonal disorder, usually beginning during the second or third decade of life. Clinical features include distal weakness, muscle atrophy, reduced sensitivity, decreased deep tendon reflexes and deformity of the foot. It may lead to the development of Charcot arthropathy, with increased osteoclastic activity and joint destruction. Ultrasonography can show effusion, synovitis, high-grade doppler activity and bone irregularities, findings that can lead to a misdiagnosis of inflammatory arthritis. CASE REPORT Male, 27-year-old, reported a history of pain and warm swelling of the left ankle and midfoot, worsening after exercise and improving with rest, that started nine years ago and persisted for one year. During this period, he self-medicated with non-steroidal anti-inflammatory drugs. He denied associated symptoms such as ocular inflammation, skin lesions, diarrhea, urethritis or fever. Ten months ago, he began to present similar symptoms in right ankle and midfoot, after a 7-year asymptomatic period.
    [Show full text]
  • Approach to Polyarthritis for the Primary Care Physician
    24 Osteopathic Family Physician (2018) 24 - 31 Osteopathic Family Physician | Volume 10, No. 5 | September / October, 2018 REVIEW ARTICLE Approach to Polyarthritis for the Primary Care Physician Arielle Freilich, DO, PGY2 & Helaine Larsen, DO Good Samaritan Hospital Medical Center, West Islip, New York KEYWORDS: Complaints of joint pain are commonly seen in clinical practice. Primary care physicians are frequently the frst practitioners to work up these complaints. Polyarthritis can be seen in a multitude of diseases. It Polyarthritis can be a challenging diagnostic process. In this article, we review the approach to diagnosing polyarthritis Synovitis joint pain in the primary care setting. Starting with history and physical, we outline the defning characteristics of various causes of arthralgia. We discuss the use of certain laboratory studies including Joint Pain sedimentation rate, antinuclear antibody, and rheumatoid factor. Aspiration of synovial fuid is often required for diagnosis, and we discuss the interpretation of possible results. Primary care physicians can Rheumatic Disease initiate the evaluation of polyarthralgia, and this article outlines a diagnostic approach. Rheumatology INTRODUCTION PATIENT HISTORY Polyarticular joint pain is a common complaint seen Although laboratory studies can shed much light on a possible diagnosis, a in primary care practices. The diferential diagnosis detailed history and physical examination remain crucial in the evaluation is extensive, thus making the diagnostic process of polyarticular symptoms. The vast diferential for polyarticular pain can difcult. A comprehensive history and physical exam be greatly narrowed using a thorough history. can help point towards the more likely etiology of the complaint. The physician must frst ensure that there are no symptoms pointing towards a more serious Emergencies diagnosis, which may require urgent management or During the initial evaluation, the physician must frst exclude any life- referral.
    [Show full text]
  • Biological Treatment in Resistant Adult-Onset Still's Disease: a Single-Center, Retrospective Cohort Study
    Arch Rheumatol 2021;36(x):i-viii doi: 10.46497/ArchRheumatol.2021.8669 ORIGINAL ARTICLE Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study Seda Çolak, Emre Tekgöz, Maghrur Mammadov, Muhammet Çınar, Sedat Yılmaz Department of Internal Medicine, Division of Rheumatology, Gülhane Training and Research Hospital, Ankara, Turkey ABSTRACT Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still’s disease (AOSD) under biological treatment. Patients and methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020. The data of the patients were obtained from the patient files. The response to the treatment was evaluated based on clinical and laboratory assessments at third and sixth follow-up visits. Results: Interleukin (IL)-1 inhibitor was prescribed for 13 (68.4%) patients and IL-6 inhibitor prescribed for six (31.6%) patients. Seventeen (89.5%) patients experienced clinical remission. Conclusion: Biological drugs seem to be effective for AOSD patients who are resistant to conventional therapies. Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved. Keywords: Adult-onset Still’s disease, anakinra, tocilizumab, treatment. Adult-onset Still’s disease (AOSD) is a rare diseases that may lead to similar clinical and systemic inflammatory disease with an unknown laboratory findings. etiology. The main clinical manifestations of It is well known that proinflammatory the disease are fever, maculopapular salmon- pink rash, arthralgia, and arthritis.
    [Show full text]
  • Differential Diagnosis of Juvenile Idiopathic Arthritis
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 3, June, 2017 https://doi.org/10.4078/jrd.2017.24.3.131 Review Article Differential Diagnosis of Juvenile Idiopathic Arthritis Young Dae Kim1, Alan V Job2, Woojin Cho2,3 1Department of Pediatrics, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea, 2Department of Orthopaedic Surgery, Albert Einstein College of Medicine, 3Department of Orthopaedic Surgery, Montefiore Medical Center, New York, USA Juvenile idiopathic arthritis (JIA) is a broad spectrum of disease defined by the presence of arthritis of unknown etiology, lasting more than six weeks duration, and occurring in children less than 16 years of age. JIA encompasses several disease categories, each with distinct clinical manifestations, laboratory findings, genetic backgrounds, and pathogenesis. JIA is classified into sev- en subtypes by the International League of Associations for Rheumatology: systemic, oligoarticular, polyarticular with and with- out rheumatoid factor, enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis. Diagnosis of the precise sub- type is an important requirement for management and research. JIA is a common chronic rheumatic disease in children and is an important cause of acute and chronic disability. Arthritis or arthritis-like symptoms may be present in many other conditions. Therefore, it is important to consider differential diagnoses for JIA that include infections, other connective tissue diseases, and malignancies. Leukemia and septic arthritis are the most important diseases that can be mistaken for JIA. The aim of this review is to provide a summary of the subtypes and differential diagnoses of JIA. (J Rheum Dis 2017;24:131-137) Key Words.
    [Show full text]
  • Spondyloarthropathies and Reactive Arthritis
    RHEUMATOLOGY SPONDYLOARTHRITIS ROBERT L. DIGIOVANNI, DO, FACOI PROGRAM DIRECTOR LMC RHEUMATOLOGY FELLOWSHIP [email protected] DISCLOSURES •NONE SERONEGATIVE SPONDYLOARTHROPATHIES SLIDES PREPARED BY GENE JALBERT, DO SENIOR RHEUMATOLOGY FELLOW THE SPONDYLOARTHROPATHIES: • Ankylosing Spondylitis (A.S.) • Non-radiographic Axial spondyloarthropathies (nr-axSpA) • Psoriatic Arthritis (PsA) • Inflammatory Bowel Disease Associated (Enteropathic) • Crohn and Ulcerative Colitis • +/- Microscopic colitis • Reactive Arthritis (ReA) • Juvenile-Onset SpA • Others: Bechet’s dz, Celiac, Whipples, pouchitis. THE FAMOUS VENN DIAGRAM: SPONDYLOARTHROPATHY: • First case of Axial SpA was reported in 1691 however some believe Ramses II has A.S. • 2.4 million adults in the United States have Seronegative SpA • Compare with RA, which affects about 1.3 million Americans • Prevalence variation for A.S.: Europe (0.12-1%), Asia (0.17%), Latin America (0.1%), Africa (0.07%), USA (0.34%). • Pathophysiology in general: • Responsible Interleukins: IL-12, IL17, IL-22, and IL23. SPONDYLOARTHROPATHY: • Axial SpA: • Radiographic (Sacroiliitis seen on X- ray) • No Radiographic features non- radiographic SpA (nr-SpA) • Nr-SpA was formally known as undifferentiated SpA • Peripheral SpA: • Enthesitis, dactylitis and arthritis • Eventually evolves into a specific diagnosis A.S., PsA, etc. • Can be a/w IBD, HLA-B27 positivity, uveitis SHARED CLINICAL FEATURES: • Axial joint disease (especially SI joints) • Asymmetrical Oligoarthritis (2-4 joints). • Dactylitis (Sausage
    [Show full text]
  • Lecture 58-Rheumatoid Arthritis and Osteoarthritis.Pdf
    Done By: Reviewed By: Ahlam Almutairi Wael Al Saleh COLOR GUIDE: • Females' Notes • Males' Notes • Important • Additional 432MedicineTeam Rheumatoid Arthritis and Osteoarthritis Objectives By the end of this lecture student should know: 1. Pathology, 2. Clinical features, 3. Laboratory and radiologic changes 4. Line of management of Rheumatoid Arthritis and Osteoarthritis 1 432MedicineTeam Rheumatoid Arthritis and Osteoarthritis Rheumatoid Arthritis Note: Systemic chronic inflammatory disease Sometimes it is called Mainly affects synovial joints rheumatoid disease because it is not • Variable expression confined to joints • Prevalence about 3% • Worldwide distribution • Female: male ratio 3:1 • Peak age of onset: 25-50 years • Unknown etiology • Genetics • Environmental • Possible infectious component • Autoimmune disorder THE PATHOLOGY OF RA o Synovitis (Joints, Tendon, sheaths& Bursae) o Nodules o Vasculitis RA Is Characterized by Synovitis and Joint Destruction Note: Pannus= part of the thickened synovia that will invade the cartilage and bone (will show in x-ray as erosion) 2 432MedicineTeam Rheumatoid Arthritis and Osteoarthritis Numerous Cellular Interactions Drive the RA Process "Trigger > activation of the T&B cells, Rheumatoid factor and autoantibodies >proteolytic enzymes, cytokines, ILs and TNF are produced> inflammation and synovial pannus formation, cartilage breakdown and bone resorption." IL-1 and TNF- Have a Number of Overlapping Proinflammatory Effects IL-1 Plays a Pivotal Role in the Inflammatory and Destructive Processes
    [Show full text]
  • Musculoskeletal Manifestations in Hyperlipidaemia: a Controlled Study
    44 Annals ofthe Rheumatic Diseases 1993; 52: 44 48 Musculoskeletal manifestations in hyperlipidaemia: Ann Rheum Dis: first published as 10.1136/ard.52.1.44 on 1 January 1993. Downloaded from a controlled study P Klemp, Anne M Halland, F L Majoos, Krisela Steyn Abstract arthritis, and oligoarthritis. '-' The reported Eighty eight patients with hyperlipidaemia (81 prevalence of these manifestations varies widely white patients from South Africa and seven from study to study because of differences in patients of mixed race from the West Cape classification of the hyperlipidaemias, patient area) were studied. Forty eight had adult selection, and study design. Interpretation of familialhypercholesterolaemia, 16had juvenile the findings, none of which included control familial hypercholesterolaemia, and 24 had patients, is difficult especially where prevalence mixed hyperlipidaemia (increased cholesterol figures are low. Migratory polyarthritis appears and triglycerides). They were interviewed and to be particularly associated with homozygous examined and their musculoskeletal mani- familial hypercholesterolaemia.' There are, festations compared with 88 controls with however, other uncontrolled studies which normal lipid profiles, and matched for age, show no specific associations between hyper- sex, and race for each group of patients. The lipidaemia and rheumatic disorders.' '1 foliowing manifestations were significantly In the one controlled study the only difference increased inthepatients: (a) tendon xanthomas between patients with hypercholesterolaemia particularly of the tendo Achiflis in patients and controls was that pain, particularly of the with adult familial hypercholesterolaemia and ankles and feet, was significantly more severe in mixed hyperlipidaemia; (b) tendo Achillis the patients." There was no difference in the tendinitis in patients with adult familial hyper- duration of morning stiffness, analgesic use, or cholesterolaemia and mixed hyperlipidaemia; effect on lifestyle.
    [Show full text]
  • Approach to the Patient with Arthritis Articular Vs
    Approach to the Patient with Arthritis Articular Vs. Periarticular Clinical feature Articular Periarticular Anatomic Synovium, Tendon, bursa, structure cartilage, ligament, capsule muscle, bone Painful site Diffuse, deep Focal “point” Pain on Active/passive, Active, in few movement all planes planes Swelling Common Uncommon Inflammatory versus Noninflammatory Arthritis Inflammatory Arthritis Noninflammatory Arthritis • Pain and stiffness typically are • Pain that worsens with worse in the morning or after periods of inactivity (the so- activity and improves with called "gel phenomenon") and rest. Stiffness is generally improve with mild to mild moderate activity. • Elevated erythrocyte • The ESR and CRP are usually sedimentation rate (ESR) and a normal. high C-reactive protein (CRP) level • The synovial fluid WBC • The synovial fluid WBC count count is is <2000/mm3 in is >2000/mm3 in inflammatory noninflammatory arthritis arthritis. Constitutional Symptoms Active infection Not due to active infection 1. Septic arthritis 1. Systemic lupus erythematosus 2. Disseminated gonococcal 2. Drug-induced lupus infection 3. Still disease 4. Gout/ Pseudogout 3. Endocarditis 5. Reactive arthritis (particularly in 4. Acute viral infections its early phases) 6. Acute rheumatic fever and 5. Mycobacterial poststreptococcal arthritis 6. Fungal 7. Inflammatory bowel disease 8. Acute sarcoidosis 9. Systemic vasculitis 10. Familial Mediterranean fever and other inherited periodic fever syndromes 11. Paraneoplastic arthritis Skin Lesions Useful in Diagnosis
    [Show full text]
  • Ankylosing Spondylitis: an Update
    Rheumatology Ankylosing spondylitis: Vera Golder an update Lionel Schachna Background Spondyloarthritis (SpA) encompasses a group of rheumatic Ankylosing spondylitis (AS) affects one in 200 individuals and disorders that share clinical, genetic and radiographic is usually diagnosed many years after onset of symptoms. features and includes psoriatic arthritis, reactive arthritis Chronic back pain is common and recognition of early disease and arthritis of inflammatory bowel disease. These requires clinical experience and a high index of suspicion. disorders affect 2–3% of the population and are twice as Further, inflammatory markers are not invariably elevated and common as rheumatoid arthritis. As they often cause long- radiographic changes are often late findings. term disability, early recognition is important. Objective The objective of this review is to address AS and the recently This review will focus on ankylosing spondylitis (AS) and the recently defined disorder of non-radiographic axial spondyloarthritis. defined disorder of non-radiographic axial SpA.1 These conditions The latter is a common early presentation of AS, before the occur in one in 200 individuals but most general practitioners have development of radiographic sacroiliitis, and will evolve into never identified a new case of AS, suggesting the need for a higher typical AS in 50% of patients. index of suspicion in primary care. Discussion MRI may be particularly useful in evaluating early disease, Clinical features although chronic changes of sacroiliitis are better seen on Back pain plain X-rays. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapy and recent studies suggest that regular Approximately 5% of chronic lower back pain is attributable to SpA.
    [Show full text]
  • Chronic Joint Pain in a Young Adult with Cystic Fibrosis
    Open Access Case Report DOI: 10.7759/cureus.17229 Chronic Joint Pain in a Young Adult With Cystic Fibrosis Bhavini B. Prajapati 1 , Alexandra Filippi 2 , Edmund H. Sears 3 1. Internal Medicine/Pediatrics, Maine Medical Center, Portland, USA 2. Pulmonary and Critical Care Medicine, Maine Medical Center, Portland, USA 3. Pulmonary Medicine, Maine Medical Center, Portland, USA Corresponding author: Bhavini B. Prajapati, [email protected] Abstract A 25-year-old male with end-stage cystic fibrosis (CF) with genotype F508del/F508del presented to the clinic complaining of bilateral knee and ankle pain. He had severe lung disease (forced expiratory volume 1 {FEV1} 19% of predicted), chronic colonization with achromobacter, malnutrition, and CF-related diabetes. On physical examination, he was found to have bilateral knee swelling as well as pain on flexion and extension of the wrists and ankles without erythema or warmth. He was empirically started on prednisone and tramadol; however, at a three-month follow-up visit, he remained symptomatic. He was sent for a whole- body bone scan, which was consistent with hypertrophic pulmonary osteoarthropathy (HPOA). He was started on highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor and symptoms spontaneously resolved without further intervention. Categories: Internal Medicine, Pulmonology, Rheumatology Keywords: hypertrophic pulmonary osteoarthropathy, cystic fibrosis, cf associated joint pain, trikafta, homozygous f508 del mutation Introduction Hypertrophic pulmonary osteoarthropathy (HPOA) is a syndrome characterized by digital clubbing, periostosis, and joint swelling. Chronic lung disease, such as that seen in patients with cystic fibrosis (CF), is a frequent association and implicated in the pathophysiology [1,2]. This condition is increasingly being recognized as a cause of chronic joint pain in patients with late-stage CF.
    [Show full text]